Compare Morgan Stanley (MS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs BIO-TECHNE Corp — how do they compare? Morgan Stanley trades at $216.93 (market cap $338.22B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.33B). The key difference: Morgan Stanley is far larger — about 29.9× BIO-TECHNE Corp's market cap, and Morgan Stanley pays the higher dividend (2.14%). Which is the better fit depends on your goals.
| MS | TECH | |
|---|---|---|
Market Cap | $338.22B | $11.33B |
Sector | Financials | Health |
52-Week High | $228.42 | $72.48 |
52-Week Low | $151.86 | $43.31 |
Dividend Yield | 2.14% | 0.44% |
Enterprise Value | — | $11.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.33, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $239.58. Revenue grew to $66.0 billion in 2025, with net income margin expanding to 25.56%, and the company has beaten EPS estimates in recent quarters. Recent news highlights its role in leading Anthropic's IPO and advancements in AI integration for wealth management.
The outlook remains positive given strong earnings momentum and strategic initiatives, though risks include volatile cash flows from operations and high leverage. Wall Street sentiment is bullish with 55.77% of analysts rating it a Buy, supporting potential upside from current levels amid broader financial sector strength.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with neutral technical signals and mixed earnings performance. The company reported Q4 2026 revenue of $321.2 million, beating estimates, but net income margins have declined from 25.09% in 2023 to 14.96% in 2026. Key developments include a pending acquisition by Merck KGaA at $73.00 per share and a quarterly dividend of $0.08. Analyst consensus is split with 46% buy and 54% hold ratings.
The stock offers moderate upside to the acquisition price, supported by solid cash flow and institutional interest, but faces risks from margin compression and ongoing shareholder investigations. Valuation multiples like P/E of 62.28 suggest premium pricing, requiring careful assessment of growth sustainability amid competitive and integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
